Hikma Pharmaceuticals (LON:HIK) had its price objective raised by Citigroup from GBX 2,100 ($27.44) to GBX 2,250 ($29.40) in a research report sent to investors on Wednesday, October 3rd. Citigroup currently has a buy rating on the stock.
A number of other research analysts have also issued reports on the company. Peel Hunt restated an add rating on shares of Hikma Pharmaceuticals in a research report on Tuesday, September 4th. Barclays reissued an underweight rating on shares of Hikma Pharmaceuticals in a research note on Monday, September 17th. JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 1,050 ($13.72) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, August 21st. Finally, Numis Securities reissued a hold rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 15th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of GBX 1,346.89 ($17.60).
Shares of HIK traded up GBX 4 ($0.05) during mid-day trading on Wednesday, hitting GBX 1,787.50 ($23.36). The stock had a trading volume of 408,615 shares, compared to its average volume of 822,138. Hikma Pharmaceuticals has a fifty-two week low of GBX 814.20 ($10.64) and a fifty-two week high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Featured Story: Understanding Analyst Recommendations
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.